相关临床试验
394
63 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
38
9.6%
已完成
219
55.6%
Enrolling By Invitation
9
2.3%
尚未招募
16
4.1%
招募中
43
10.9%
暂停
1
0.3%
终止
5
1.3%
Unknown
59
15.0%
撤回
4
1.0%
暂无批准数据
- Professor Mike Sathekge receives the 2025 Harry Oppenheimer Fellowship Award, a R3 million grant, to develop a Trop2-targeted theranostic approach for breast cancer. - The research combines nanobody-based PET/CT imaging with actinium-225 targeted alpha therapy to enable earlier detection and personalised treatment of aggressive breast cancers. - In South Africa, 67% of breast cancer patients are diagnosed at late stage, highlighting the urgent need for improved diagnostic and therapeutic strategies. - The collaboration with KU Leuven aims to create a clinically scalable system linking Trop2 imaging directly to targeted radionuclide therapy, potentially transforming breast cancer into a manageable disease.
- Beactica Therapeutics and KU Leuven received a prestigious €2.5 million European Innovation Council grant to advance BEA-17, a first-in-class LSD1-CoREST degrader for glioblastoma treatment. - The 30-month GLIOBREAK project aims to complete IND-enabling studies and submit regulatory applications to FDA or EMA for first-in-human trials. - BEA-17 has demonstrated promising preclinical results by restoring immune activity in tumor microenvironments and shows good blood-brain barrier penetration with FDA Orphan Drug Designation. - Glioblastoma affects approximately 35,000 patients annually in the U.S. and Europe, with a devastating median survival of only 15 months and 5% five-year survival rate.
- Hemastatx, a new KU Leuven spin-off, has developed the first therapy to address the underlying mechanism of von Willebrand factor defects, a severe bleeding disorder affecting 100,000 hospitalized patients annually worldwide. - The company's novel antibody therapy targets ADAMTS13, a molecular scissor that excessively degrades von Willebrand factor in affected patients, restoring blood clotting function and halting bleeding episodes. - The spin-off secured seed funding from international investors including Swiss accelerator BaseLaunch, the Butterfly Fund, and KU Leuven's Gemma Frisius Fund to advance preclinical development and prepare for clinical trials.
- Researchers at KU Leuven have developed a novel dual-agent approach that renders HIV permanently harmless by forcing the virus into a deep dormant state. - The method combines two medicines: one that disables the virus's integration "GPS system" and another that blocks alternative integration sites in human DNA. - While the approach shows promise in laboratory studies on human cells, extensive clinical research is still needed before human trials can begin. - The breakthrough could potentially eliminate the need for lifelong antiretroviral therapy in HIV patients, addressing a major limitation of current treatments.
- eXmoor Pharma and KU Leuven have established a strategic partnership to support a new cell and gene therapy hub, focusing on accelerating AAV gene therapies from bench to first-in-human trials. - The collaboration will develop a proprietary AAV producer cell line, build a scalable platform process, and provide comprehensive CMC support, combining KU Leuven's academic innovation with eXmoor's manufacturing expertise. - This alliance aims to address critical bottlenecks in gene therapy development by streamlining translation pathways and ensuring cost-effective, scalable vector production for promising therapeutic candidates.
- KU Leuven and UZ Leuven are investing €14 million to establish an Advanced Therapy Medicinal Products (ATMP) facility on the Gasthuisberg campus, scheduled to be operational by late 2025. - The facility aims to develop personalized cell and gene therapies at significantly lower costs than pharmaceutical companies, with projects focusing on rare pediatric diseases, CAR-T cell therapy for leukemia, and a glioblastoma cancer vaccine. - By keeping expertise and production in-house within the public domain, the facility expects to bring treatments to clinical trials for approximately €5 million, compared to the €25-50 million typically required by pharmaceutical companies.
